Vaxart (STU:NB11) Short Interest


STU:NB11 Vaxart Inc STU:NB11
59 GF Score
Price €0.60
GF Value €9.39
! 3 Warning Signs
View Full Analysis

What is Vaxart Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:NB11 vs SPRO, ADCT, GNLX: Short Interest Comparison

For the Biotechnology subindustry, Vaxart's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Short Interest distribution charts can be found below:

* The bar in red indicates where Vaxart's Short Interest falls into.


STU:NB11
59GF Score
Vaxart Inc STU:NB11
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vaxart (STU:NB11) Overvalued in 2026?

Based on GuruFocus' analysis, Vaxart stock appears to be undervalued. The current stock price of €0.60 is trading 93.6% below its estimated GF Value™ of €9.39.

Key valuation signals for STU:NB11:

  • Short Interest:
  • GF Value™: €9.39 vs. price of €0.60 (93.6% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the STU:NB11 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
59GF Score

Get the complete analysis for STU:NB11

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€9.39
GF Value